Clinical Trial Update: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial update for ATA3219 in relapsed/refractory B-cell non-Hodgkin lymphoma notes that the study has been terminated, with safety and preliminary effi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• ATA3219

Snippet

Sponsor: Atara Biotherapeutics | Conditions: Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Status: TERMINATED